EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Does 18F-sodium fluoride PET/CT have a role in the assessment of response to 223Ra therapy in men with prostatic bone metastases?

Glen M Blake iD, Ricardo Donners, Amelia E B Moore, Holly Tovey, Aude Espinasse, Matthew D Blackledge, Sue Chua, Yong Du, Emma Hall, Dow-Mu Koh, Emilia Nuzzaci, Nina Tunariu und 2 weitere

European Journal of Nuclear Medicine and Molecular Imaging · 2026

DOI: 10.1007/s00259-026-08009-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2026. Verfasst von Glen M Blake und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, School of Biomedical Engineering & Imaging Sciences, King's College London, St Thomas' Hospital, London, UK. gl…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Positron Emission Tomography Computed Tomography, Sodium Fluoride, Bone Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The REASURE study investigated imaging biomarkers in men receiving 223 Ra treatment for prostate cancer bone metastases. We used REASURE data to compare and contrast the roles of [ 18 F]NaF PET/CT measurements of maximum standardised uptake value (SUVmax) and bone metabolic flux (Ki) as markers of response.

Methods

Thirty-four men with prostatic bone metastases received up to six cycles of 223 Ra (55 or 88 kBq/kg) at four-weekly intervals. Whole-body diffusion-weighted MRI and [ 18 F]NaF PET/CT images were acquired at baseline and 4, 12, and 24 weeks later. Values of the apparent diffusion coefficient (ADC, a measure of tumour response), SUVmax, and a novel surrogate measurement of Ki using a PET/CT SUV measurement in the left ventricle were monitored in up to 5 bone metastases in each participant. Multilinear regression analysis (MLR) was performed to determine if changes in ADC were predicted by changes in SUVmax or Ki. Radium dose and baseline SUVmax were additional independent variables.

Results

ADC values increased throughout the study, while SUVmax and Ki decreased. MLR analysis showed that baseline SUVmax and 223 Ra dose predicted ADC response ( P < 0.001 and P < 0.01, respectively). Changes in SUVmax and Ki at 4, 12, and 24 weeks failed to predict the changes in ADC, showing decoupling between MRI and PET/CT measurements as markers of response. Changes in Ki were a highly significant predictor of changes in SUVmax ( P < 0.001), reflecting the strong correlation between these two measurements.

Conclusions

Baseline SUVmax was the best predictor of ADC response, followed by 223 Ra dose. Changes in SUVmax and Ki failed to predict changes in ADC, suggesting that the changes in the PET/CT variables reflected the effect of 223 Ra uptake on osteoblasts rather than a tumoricidal effect. A decrease in SUVmax seen on post-therapy [ 18 F]NaF PET/CT scans should not be interpreted as evidence of tumour regression. Trial Registration ISRCTN ISRCTN17805587. Registered 21/01/15.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsPositron Emission Tomography Computed TomographySodium FluorideBone NeoplasmsFluorine RadioisotopesRadiumHumansMaleAgedTreatment OutcomeMiddle Aged

Stichwörter der Autor:innen

18F]NaF PET/CT imagingBone metabolic flux (Ki)Bone metastasesDiffusion-weighted MRIMaximum standardised uptake valuesProstate cancerRadium-223 therapy

Substanzen

Sodium FluorideFluorine RadioisotopesRadiumFluorine-18Radium-223

Autor:innen und Institutionen

  • Department of Biomedical Engineering, School of Biomedical Engineering & Imaging Sciences, King's College London, St Thomas' Hospital, London, UK. glen.blake@kcl.ac.uk.
  • Department of Radiology, University Hospital Basel, Petersgraben 4, Basel, 4031, Switzerland.
  • Department of Cancer Imaging, School of Biomedical Engineering & Imaging Sciences, King's College London, St Thomas' Hospital, London, UK.
  • The Institute of Cancer Research, 15 Cotswold Road, Sutton, SM2 5NG, UK.
  • Royal Marsden Hospital, Downs Road, Sutton, SM2 5PT, UK.

ORCID-Profile: Glen M Blake

Zitieren

APA

Blake, G. M., Donners, R., Moore, A. E. B., Tovey, H., Espinasse, A., Blackledge, M. D., Chua, S., Du, Y., Hall, E., Koh, D. M., Nuzzaci, E., Tunariu, N., Parker, C. C., & Cook, G. J. R. (2026). Does 18F-sodium fluoride PET/CT have a role in the assessment of response to 223Ra therapy in men with prostatic bone metastases?. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-026-08009-8

Vancouver

Blake GM, Donners R, Moore AEB, Tovey H, Espinasse A, Blackledge MD, et al. Does 18F-sodium fluoride PET/CT have a role in the assessment of response to 223Ra therapy in men with prostatic bone metastases?. European Journal of Nuclear Medicine and Molecular Imaging. 2026. doi:10.1007/s00259-026-08009-8

BibTeX
@article{Blake2026,
  author = {Blake, Glen M and Donners, Ricardo and Moore, Amelia E B and Tovey, Holly and Espinasse, Aude and Blackledge, Matthew D and Chua, Sue and Du, Yong and Hall, Emma and Koh, Dow-Mu and Nuzzaci, Emilia and Tunariu, Nina and Parker, Christopher C and Cook, Gary J R},
  title = {Does 18F-sodium fluoride PET/CT have a role in the assessment of response to 223Ra therapy in men with prostatic bone metastases?},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  doi = {10.1007/s00259-026-08009-8}
}
Kostenlos starten →